Presentation Detail
- Speaker: Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
- Date: October 17, 2019
Research Abstract
Introduction
For a life-threatening disease like cancer, optimal treatment may need to be personalized for each patient. We developed a functional precision medicine platform based on a novel chemosensitivity assay to identify effective drugs most likely to benefit an individual canine lymphoma patient, ultimately enabling veterinary oncologists to treat lymphoma with an individualized regimen. This study evaluated the correlation between our ex vivo data-driven prediction and reported responses in a series of canine lymphoma patients.
Methods
We performed our ex vivo drug sensitivity assay on live cancer cells from fresh fine needle aspirates taken from affected lymph nodes of canine lymphoma patients. The drug panel included 12 antineoplastic drugs and 2 corticosteroids commonly used for canine lymphoma treatment. 218 correlations between drug response prediction and clinical outcome were evaluated retrospectively in 66 canine lymphoma patients provided by 8 clinical sites, by collecting the patient’s previous treatment history and the post-treatment clinical outcome 60–90days after the prediction report.
Results
Each of the 64 lymphoma patients showed a unique drug response profile from the ex vivo chemosensitivity test. The positive predictive value of the test was 84.0% and the negative predictive value was 88.6% with 77.3% sensitivity and 92.3% specificity.
Conclusion
The ex vivo drug sensitivity test developed in this study may provide predictive information on chemotherapy sensitivity for canine lymphoma and improve treatment outcomes individual patients.
Funding Information
This study was funded by ImpriMed, Inc.
